Editas Medicine (Nasdaq: EDIT) trims Q1 2026 net loss to $25M
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Editas Medicine reported first quarter 2026 results and highlighted progress on its lead in vivo gene-editing program, EDIT-401, for hyperlipidemia and HeFH. Preclinical data showed more than 90% mean LDL-C reduction, and the company plans to start a first-in-human trial in 2026 with early proof-of-concept data expected by year-end and dose-finding topline data in 2027.
Cash and cash equivalents were $123.6 million as of March 31, 2026, which the company expects will fund operations into the third quarter of 2027. Net loss narrowed to $25.0 million, or $0.26 per share, compared with a net loss of $76.1 million, or $0.92 per share, a year earlier, driven by lower R&D and G&A expenses and the absence of prior-year restructuring and impairment charges.
Collaboration and other research and development revenues were $2.8 million, down from $4.7 million in the prior-year quarter, primarily because 2025 included remaining deferred revenue recognized when a collaboration ended. The U.S. Patent and Trademark Office also reaffirmed a prior Patent Trial and Appeal Board decision favoring the Broad Institute in a CRISPR/Cas9 interference involving patents exclusively licensed to Editas for use in human cells.
Positive
- None.
Negative
- None.
Insights
Loss narrows sharply as Editas pivots to in vivo gene editing.
Editas Medicine significantly reduced its quarterly net loss to $25.0M from $76.1M while advancing its in vivo CRISPR program EDIT-401 toward the clinic. Lower R&D and G&A expenses and no restructuring charges drove the improvement.
The company ended March 31, 2026 with $123.6M in cash and cash equivalents and projects a runway into Q3 2027, giving it time to generate early human data. EDIT-401 has shown >90% LDL-C reduction in preclinical models and additional effects on Lp(a) and ApoB.
Key milestones are initiation of the first-in-human HeFH trial later in 2026, early proof-of-concept by year-end 2026, and dose-finding topline data in 2027. Future updates on clinical safety, LDL-C lowering, and durability will be central to assessing the program’s potential.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Net loss: $25.0M
Net loss prior year: $76.1M
EPS: $0.26 loss per share
+5 more
8 metrics
Net loss
$25.0M
Net loss attributable to common stockholders, Q1 2026
Net loss prior year
$76.1M
Net loss attributable to common stockholders, Q1 2025
EPS
$0.26 loss per share
Basic and diluted net loss per share, Q1 2026
Collaboration revenue
$2.8M
Collaboration and other R&D revenues, Q1 2026
Research and development expense
$17.6M
R&D expenses for the three months ended March 31, 2026
General and administrative expense
$10.2M
G&A expenses for the three months ended March 31, 2026
Cash and cash equivalents
$123.6M
Cash and cash equivalents as of March 31, 2026
Cash runway
Into Q3 2027
Management expectation for funding operating expenses and capex
Key Terms
in vivo CRISPR gene editing, Good Laboratory Practice (GLP) toxicology study, Heterozygous Familial Hypercholesterolemia (HeFH), restructuring and impairment charges, +2 more
6 terms
in vivo CRISPR gene editing technical
"a potentially transformative in vivo gene editing medicine designed to treat hyperlipidemia"
Good Laboratory Practice (GLP) toxicology study technical
"including the Good Laboratory Practice (GLP) toxicology study in non-human primates"
Heterozygous Familial Hypercholesterolemia (HeFH) medical
"a first-in-human clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH)"
restructuring and impairment charges financial
"the Company recorded no restructuring and impairment charges compared to $40.9 million"
Restructuring and impairment charges are accounting entries that reflect costs from reorganizing a business and from recognizing that assets are worth less than previously recorded. Think of restructuring as paying to rearrange or shrink your operations (like closing a shop or laying off staff), and impairment as writing down the value of an asset that no longer earns as much as expected (like admitting an old machine is obsolete). They matter to investors because they reduce reported profits, can signal management action or deeper problems, and affect future cash flows and valuation.
Patent Trial and Appeal Board (PTAB) regulatory
"reaffirmed the Patent Trial and Appeal Board’s (PTAB’s) previous decision favoring the Broad Institute"
The Patent Trial and Appeal Board (PTAB) is an administrative tribunal within the U.S. patent office that reviews challenges to the validity of issued patents, acting like a referee who can confirm, narrow, or cancel patent rights. Investors care because PTAB decisions can make a company’s patent portfolio stronger or weaker, which affects future revenue from products, licensing opportunities, and the risk of costly lawsuits, much like a ruling that changes the rules of the game.
patent interference regulatory
"in the U.S. patent interference involving specific patents exclusively licensed to Editas Medicine"
Earnings Snapshot
Net loss: $25.0M · Guidance included
Q1 2026
Net loss
$25.0M
vs $76.1M in Q1 2025
EPS (basic and diluted)
$0.26 loss
vs $0.92 loss in Q1 2025
Collaboration and other R&D revenues
$2.8M
vs $4.7M in Q1 2025
Research and development expenses
$17.6M
vs $26.6M in Q1 2025
General and administrative expenses
$10.2M
vs $13.4M in Q1 2025
Guidance
The company expects existing cash and cash equivalents to fund operating expenses and capital expenditure requirements into the third quarter of 2027.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________________________________________
FORM 8-K
_________________________________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 5, 2026
_________________________________________________________________________________________
(Exact Name of Registrant as Specified in its Charter)
_________________________________________________________________________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s telephone number, including area code: (617 ) 401-9000
(Former Name or Former Address, if Changed Since Last Report)
__________________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On May 5, 2026 , Editas Medicine, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended March 31, 2026 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press release issued by the Company on May 5, 2026* | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
*This exhibit shall be deemed to be furnished and not filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EDITAS MEDICINE, INC. | ||||||||
Date: | By: | /s/ Amy Parison | ||||||
| Amy Parison | ||||||||
| Chief Financial Officer | ||||||||
Editas Medicine Announces First Quarter 2026 Results and Business Updates
EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026
Company to present new EDIT-401 preclinical data at upcoming scientific meetings, including data showing significant reductions in Lp(a) and ApoB in non-human primates at the 94th EAS Congress
U.S. Patent and Trademark Office reaffirmed prior decision in favor of the Broad Institute in CRISPR/Cas9 interference
CAMBRIDGE, Mass., May 5, 2026 – Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the first quarter 2026 and provided business updates.
“In the first quarter, we continued to advance EDIT-401, a potentially transformative in vivo gene editing medicine designed to treat hyperlipidemia, toward the clinic,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. “We are highly encouraged by our recent preclinical safety and efficacy data, including emerging data from our GLP toxicology study, as well as data demonstrating EDIT-401’s ability to reduce multiple independent risk factors for atherosclerotic cardiovascular disease, including LDL-C, Lp(a), and ApoB, in non-human primates. Based on these data, we believe EDIT-401 has a potential best-in-class profile as a one-time treatment for hyperlipidemia, and we remain on track to initiate a first-in-human study with early human proof-of-concept data by year end.”
Upcoming Data Presentations
American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting, May 11-15
•Preclinical Development of EDIT-401, a Durable In Vivo CRISPR Gene Editing Therapy That Upregulates LDLR Protein to Lower LDL-C
•Pharmacokinetics and Pharmacodynamics of EDIT-401(mu), an In Vivo Gene Editing Therapy for Lowering LDL-C in Mice
•In vivo CRISPR-based Disruption of an Important Gene Repressor Element Upregulates a Compensatory Protein to Normalize Disease-Associated Biomarkers in a Knockout Mouse Disease Model
TIDES USA 2025: Oligonucleotide & Peptide Therapeutics, May 11-14
•Transformative LDL Cholesterol Lowering In Vivo CRISPR Gene Editing Approach for Hyperlipidemia and Atherosclerotic Cardiovascular Disease
94th European Atherosclerosis Society (EAS) Congress, May 24-27
•A Transformative In Vivo CRISPR Gene Editing Medicine Upregulates LDLR and Meaningfully Reduces LDL-C in Non-Human Primates
2026 National Lipid Association (NLA) Sessions, June 11-14
•A Transformative In Vivo CRISPR Gene Editing Medicine Leads to Upregulation of LDLR and Robust Reduction of Two Independent ASCVD Risk Factors, LDL-C and Lp(a), in Preclinical Studies
EDIT-401
•Editas continues to advance preclinical studies for its lead in vivo development candidate, EDIT-401, including the Good Laboratory Practice (GLP) toxicology study in non-human primates to support advancement into a first-in-human clinical trial.
•The Company is preparing to initiate a first-in-human clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH) later this year, and expects to have early human proof-of-concept data by the end of 2026.
•Editas plans to complete enrolling the dose-finding portion of the first-in-human clinical trial of EDIT-401 with topline data results available in 2027.
Intellectual Property
•On March 26, the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s (PTAB’s) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents exclusively licensed to Editas Medicine for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and the Broad Institute, Massachusetts Institute of Technology, and Harvard University (collectively, Broad).
•This action by the PTAB is its third favorable decision determining that Broad was the first to invent the use of CRISPR/Cas9 for gene editing in eukaryotic cells, including human cells. CVC retains the right to appeal the decision.
Upcoming Events
Editas Medicine plans to participate in the following investor event:
•2026 Jefferies Global Healthcare Conference
Format: Presentation
Date: June 4, 2026
Time: 4:20 p.m. ET
New York, NY
To access a live webcast of the investor presentation, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the event.
First Quarter 2026 Financial Results
Cash and cash equivalents as of March 31, 2026, were $123.6 million compared to $146.6 million as of December 31, 2025. The Company expects that the existing cash and cash equivalents will enable the Company to fund its operating expenses and capital expenditure requirements into the third quarter of 2027.
First Quarter 2026
•For the three months ended March 31, 2026, net loss attributable to common stockholders was $25.0 million, or $0.26 per share, compared to net loss of $76.1 million, or $0.92 per share, for the same period in 2025.
•Collaboration and other research and development revenues decreased to $2.8 million for the three months ended March 31, 2026, compared to $4.7 million for the same period in 2025. The decrease is primarily attributable to the recognition of the remaining deferred revenue upon conclusion of a collaboration agreement with a strategic partner in 2025.
•Research and development expenses decreased by $9.0 million to $17.6 million for the three months ended March 31, 2026, compared to $26.6 million for the same period in 2025. The decrease is primarily related to reduced headcount (the “Reduction”) and decreased clinical and manufacturing costs related to discontinuation of the clinical development of the Company’s reni-cel program (the “Discontinuation”) initiated in December 2024 and ongoing throughout 2025, partially offset by costs attributable to in vivo research and discovery in 2026 and increased sublicense and license fees.
•General and administrative expenses decreased by $3.1 million to $10.2 million for the three months ended March 31, 2026, compared to $13.4 million for the same period in 2025. The decrease is primarily attributable to a reduction in employee-related expenses related to the Reduction, as well as reduced professional services in connection with the discontinuation of the clinical development of the Company’s reni-cel program initiated in December 2024 and ongoing throughout 2025.
•For the three months ended March 31, 2026, the Company recorded no restructuring and impairment charges compared to $40.9 million for the same period in 2025. The restructuring and impairment charges for the three months ended March 31, 2025 were primarily attributable to reni-cel related contract costs, accelerated expense recognized due to changes in useful life estimates for leasehold improvements, software, and a right-of-use asset, and impairment charges related to the sale of certain assets, resulting from the actions associated with the Discontinuation and the Reduction.
About Heterozygous Familial Hypercholesterolemia (HeFH)
Heterozygous Familial Hypercholesterolemia (HeFH) is an inherited genetic disorder that leads to significantly elevated LDL‑cholesterol levels from an early age. Individuals with HeFH are at high risk of heart disease, heart attack, or stroke if the condition is not identified and treated early. An estimated 1.2 million people in the United States are living with HeFH, though many remain undiagnosed. Elevated LDL-C, also known as hyperlipidemia, is a highly prevalent disease affecting over 70 million patients in the United States alone. Substantial unmet need exists across multiple at-risk segments of patients with hyperlipidemia, including the HeFH population.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the initiation, timing, progress and results of the Company’s preclinical studies and planned clinical trials, including the Company’s expectation to initiate a first-in-human clinical trial of EDIT-401 later this year, achieve early human proof-of-concept data for EDIT-401 by year-end 2026, and complete enrolling the dose-finding portion of the EDIT-401 clinical trial with topline data results available in 2027; the timing for the Company’s receipt and presentation of data from its preclinical studies; the potential of, and expectations for, EDIT-401 and the Company’s other future in vivo product candidates; the timing or likelihood of regulatory submissions and approvals; and the Company’s expectations regarding its cash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking
statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation, timing, progress, and results of preclinical studies and clinical trials; uncertainty regarding availability and timing of results from preclinical studies and clinical trials; uncertainties relating to planned regulatory submissions to initiate clinical trials, including that results of preclinical studies will warrant such submissions or that regulatory agencies may require additional preclinical studies, that regulatory submissions shall occur on the expected timelines and that regulatory authorities will provide clearance for trials to be initiated; and that the Company will not be able to raise funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
EDITAS MEDICINE, INC.
Consolidated Statement of Operations
(amounts in thousands, except share and per share data)
(Unaudited)
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| Collaboration and other research and development revenues | $ | 2,831 | $ | 4,658 | |||||||
| Operating expenses: | |||||||||||
| Research and development | 17,600 | 26,593 | |||||||||
| General and administrative | 10,234 | 13,375 | |||||||||
| Restructuring and impairment charges | — | 40,853 | |||||||||
| Total operating expenses | 27,834 | 80,821 | |||||||||
| Operating loss | (25,003) | (76,163) | |||||||||
| Other income, net: | |||||||||||
| Interest expense related to sale of future revenues | (1,072) | (2,216) | |||||||||
| Interest income, net | 1,206 | 2,716 | |||||||||
| Other expense, net | (113) | (425) | |||||||||
| Total other income, net | 21 | 75 | |||||||||
| Net loss | $ | (24,982) | $ | (76,088) | |||||||
| Net loss per share, basic and diluted | $ | (0.26) | $ | (0.92) | |||||||
| Weighted-average common shares outstanding, basic and diluted | 97,879,343 | 83,055,066 | |||||||||
EDITAS MEDICINE, INC.
Selected Consolidated Balance Sheet Items
(amounts in thousands)
(Unaudited)
| March 31, | December 31, | ||||||||||
| 2026 | 2025 | ||||||||||
| Cash and cash equivalents | $ | 123,648 | $ | 146,645 | |||||||
| Working capital | 88,287 | 117,649 | |||||||||
| Total assets | 149,338 | 186,534 | |||||||||
| Deferred revenue, net of current portion | 44,509 | 44,509 | |||||||||
| Total stockholders' equity | 4,408 | 27,288 | |||||||||
###
Investor and Media Contacts:
ir@editasmed.com
media@editasmed.com